LIP
INDV icon

Liontrust Investment Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Liontrust Investment Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,326,647
Closed -$17M – 244
2024
Q4 		$17M Sell
1,326,647
-42,627
-3% -$439K 0.25% 71
2024
Q3 		$21.5M Hold
1,369,274
– – 0.3% 65
2024
Q2 		$21.5M Sell
1,369,274
-8,617
-0.6% -$156K 0.3% 65
2024
Q1 		$23.3M Sell
1,377,891
-109,586
-7% -$2.06M 0.33% 57
2023
Q4 		$22.5M Sell
1,487,477
-508,412
-25% -$9.03M 0.33% 56
2023
Q3 		$43.3M Buy
+1,995,889
New +$45.5M 0.69% 37

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Liontrust Investment Partners's INDV Position: Q1 2025 in Review

Liontrust Investment Partners sold out of Indivior Pharmaceuticals (INDV) in Q1 2025, closing a stake of 1,326,647 shares — an estimated $17M sold.

Liontrust Investment Partners first reported a position in INDV in Q3 2023 and held it in 6 quarters. The position peaked at $43.3M in Q3 2023. 116 funds tracked by Wall St. Rank hold INDV as of Q1 2025.

  • Liontrust Investment Partners reported no remaining Indivior Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Liontrust Investment Partners sold 1,326,647 Indivior Pharmaceuticals shares in Q1 2025, an estimated $17M.
  • Liontrust Investment Partners first reported a position in Indivior Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • Liontrust Investment Partners's Indivior Pharmaceuticals position peaked at $43.3M in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2025.

Based on Liontrust Investment Partners's 13F filing for Q1 2025, filed 13 May 2025.